BIOS Capital Management, LP

FORT WORTH, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$34.2M2026 Q3
Positions6
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

BIOS Capital Management, LP reported 6 positions worth $34.2M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: IRD (52.2%). Biggest move: reduce LTRN ($13.6K).

6 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 IRDOpus Genetics$17.8M52.17%3,683,429——-16.5%
▸ 2 ACTUActuate Therapeutics$7.8M22.94%10,049,996——-63.4%
▸ 3 CGTXCognition Therapeutics$5.8M16.86%6,000,000———
▸ 4 RNTXRein Therapeutics$2.4M7.02%2,982,375———
▸ 5 LTRNLantern Pharma$238.3K0.70%235,895———
▸ 6 INABIN8BIO$107.7K0.32%80,957———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does BIOS Capital Management, LP hold as of Q3 2026?

BIOS Capital Management, LP reported 6 positions worth $34.2M in its Q3 2026 13F filing. Largest positions: IRD (52.2%), ACTU (22.9%), CGTX (16.9%), RNTX (7.0%) and LTRN (0.7%).

What did BIOS Capital Management, LP buy in Q3 2026?

BIOS Capital Management, LP opened or added to no positions in Q3 2026.

What did BIOS Capital Management, LP sell in Q3 2026?

Reduced: LTRN.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.